انتقل إلى وضع عدم الاتصال باستخدام تطبيق Player FM !
Episode 23. Bispecific Antibodies in Myeloma
Manage episode 364812224 series 3369804
In this episode, we delve into the latest data on bispecific antibodies in multiple myeloma with Dr. Ajai Chari. Here are the key studies discussed:
1. Teclistamab (MajesTEC-1 trial): https://pubmed.ncbi.nlm.nih.gov/35661166/
2. Correlative analysis from MajesTEC-1 trial: https://ashpublications.org/blood/article/140/Supplement%201/241/487619
3. Talquetamab (MonumenTAL-1 trial): https://pubmed.ncbi.nlm.nih.gov/36507686/
4. Phase 1 trial of fixed-duration cevostamab:
https://ashpublications.org/blood/article/140/Supplement%201/4415/492339
5. Phase 1 trial of ABBV-383: https://pubmed.ncbi.nlm.nih.gov/36029527/
6. Paper summarizing infections with different bispecific antibodies in myeloma: https://pubmed.ncbi.nlm.nih.gov/36716411/
52 حلقات
Manage episode 364812224 series 3369804
In this episode, we delve into the latest data on bispecific antibodies in multiple myeloma with Dr. Ajai Chari. Here are the key studies discussed:
1. Teclistamab (MajesTEC-1 trial): https://pubmed.ncbi.nlm.nih.gov/35661166/
2. Correlative analysis from MajesTEC-1 trial: https://ashpublications.org/blood/article/140/Supplement%201/241/487619
3. Talquetamab (MonumenTAL-1 trial): https://pubmed.ncbi.nlm.nih.gov/36507686/
4. Phase 1 trial of fixed-duration cevostamab:
https://ashpublications.org/blood/article/140/Supplement%201/4415/492339
5. Phase 1 trial of ABBV-383: https://pubmed.ncbi.nlm.nih.gov/36029527/
6. Paper summarizing infections with different bispecific antibodies in myeloma: https://pubmed.ncbi.nlm.nih.gov/36716411/
52 حلقات
ทุกตอน
×مرحبًا بك في مشغل أف ام!
يقوم برنامج مشغل أف أم بمسح الويب للحصول على بودكاست عالية الجودة لتستمتع بها الآن. إنه أفضل تطبيق بودكاست ويعمل على أجهزة اندرويد والأيفون والويب. قم بالتسجيل لمزامنة الاشتراكات عبر الأجهزة.